Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22354643 | 0.89 | HSD17B10 (0.39) | HSD17B10S1PR1SLC6A9CYP1A2ALOX15 | |
| SCHEMBL22344784 | 0.84 | HSD17B10 (0.40) | HSD17B10S1PR1SLC6A9SMN1; SMN2CYP1A2 | |
| SCHEMBL22344786 | 0.84 | HSD17B10 (0.40) | HSD17B10S1PR1SLC6A9SMN1; SMN2CYP1A2 | |
| SCHEMBL22779191 | 0.82 | SMN1; SMN2 (0.40) | HSD17B10S1PR1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL26434198 | 0.82 | HSD17B10 (0.36) | HSD17B10S1PR1SLC6A9CACNA1HAPEX1 | |
| SCHEMBL19016168 | 0.82 | HSD17B10 (0.36) | HSD17B10S1PR1SLC6A9CACNA1HAPEX1 | |
| SCHEMBL22354582 | 0.82 | HSD17B10 (0.36) | HSD17B10S1PR1SLC6A9SMN1; SMN2APEX1 | |
| SCHEMBL10735957 | 0.81 | CYP2C19 (0.34) | SMN1; SMN2ALOX15 | |
| SCHEMBL18803169 | 0.78 | PAOX (0.38) | SMN1; SMN2SIGMAR1 | |
| SCHEMBL15499754 | 0.78 | HSD17B10 (0.48) | HSD17B10S1PR1SLC6A9SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127047-A1 | SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES | ANTAROS MEDICAL AB (SE) | 2023-04-27 | — | — | US | disclosed |
| WO-2021198229-A1 | SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES | ANTAROS MEDICAL AB (SE) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127047-A1 | SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES | GIPR, GRPR, GLP1R | HSD17B10 4682/4885S1PR1 460/4885SLC6A9 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.